Invacare 2012 Annual Report Download - page 127

Download and view the complete annual report

Please find page 127 of the 2012 Invacare annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 152

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152

INVACARE CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
intellectual property impairment of $201,000 in the Asia/Pacific segment. The fair value of the customer lists
were calculated using an excess earnings method, using a discounted cash flow model. Estimated cash flow
returns to the customer relationship were reduced by the cash flows required to satisfy the return requirements of
each of the assets employed with the residual cash flow then discounted to value the customer relationship. The
fair value of the trademark was calculated using a relief from royalty payment methodology which requires
applying an estimated market royalty rate to forecasted net sales and discounting the resulting cash flows to
determine fair value. The intellectual properly intangible asset was impaired as the intellectual property was
deemed no longer viable and is no longer being used.
As a result of the company’s 2010 intangible impairment review, the company calculated the fair value of
an IPG segment indefinite-lived trademark and a NA/HME segment customer list as each had indicators of
impairment, principally net sales less than forecasted. The fair value of the trademark was calculated using a
relief from royalty payment methodology which requires applying an estimated market royalty rate to forecasted
net sales and discounting the resulting cash flows to determine fair value. The calculated fair value resulted in an
impairment charge of $336,000 for the IPG segment indefinite-lived trademark. The fair value of the customer
list was calculated using an excess earnings method, using a discounted cash flow model. Estimated cash flow
returns to the customer relationship were reduced by the cash flows required to satisfy the return requirements of
each of the assets employed with the residual cash flow then discounted to value the customer relationship. The
calculated fair value resulted in an impairment charge of $248,000 for the NA/HME segment customer list.
The fair values of the company’s intangible assets were calculated using inputs that are not observable in the
market and included management’s own estimates regarding the assumptions that market participants would use
and thus these inputs are deemed Level III inputs in regards to the fair value hierarchy.
Business Segments
The company operates in four primary business segments: North America/Home Medical Equipment (NA/
HME), Institutional Products Group (IPG), Europe and Asia/Pacific.
The NA/HME segment sells each of three primary product lines, which includes: lifestyle, mobility and
seating and respiratory therapy products. The Institutional Products Group sells or rents long-term care medical
equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell the same product lines
as NA/HME and IPG. Each business segment sells to the home health care, retail and extended care markets.
The company evaluates performance and allocates resources based on profit or loss from operations before
income taxes for each reportable segment. The accounting policies of each segment are the same as those
described in the summary of significant accounting policies for the company’s consolidated financial statements.
Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element.
Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating
segment performance except for Asia/Pacific due to its significant intercompany sales volume.
FS-47